CNR1 and obesity disorder: Importantly, hyperactivation of CB1R downstream signaling correlates with obesity and type 2 diabetes, whereas its blockade by the first-generation CB1R inverse agonist Rimonabant, also named SR141716A by the original manufacturer, leads to considerable lowering of the body weight in laboratory animals and obese patients [5].